Skip to main navigation Skip to search Skip to main content

Survival Impact of Repeated Endobiliary Radiofrequency Ablation in Patients Undergoing Durvalumab Plus Gemcitabine and Cisplatin for Extrahepatic Cholangiocarcinoma: An International Multicenter Randomized Controlled Trial (BRAVE Trial)

Press/Media

Period3 Dec 2025

Media coverage

1

Media coverage

  • TitleSurvival Impact of Repeated Endobiliary Radiofrequency Ablation in Patients Undergoing Durvalumab Plus Gemcitabine and Cisplatin for Extrahepatic Cholangiocarcinoma: An International Multicenter Randomized Controlled Trial (BRAVE Trial)
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date3/12/25
    PersonsHee Jae Jung
View all 1
View less